Holt DW - Search Results

1

Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus.

Sindhi R, Webber S, Venkataramanan R, McGhee W, Phillips S, Smith A, Baird C, Iurlano K, Mazariegos G, Cooperstone B, Holt DW, Zeevi A, Fung JJ, Reyes J. Sindhi R, et al. Among authors: holt dw. Transplantation. 2001 Sep 15;72(5):851-5. doi: 10.1097/00007890-200109150-00019. Transplantation. 2001. PMID: 11571449

2

Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients.

Schubert M, Venkataramanan R, Holt DW, Shaw LM, McGhee W, Reyes J, Webber S, Sindhi R. Schubert M, et al. Among authors: holt dw. Am J Transplant. 2004 May;4(5):767-73. doi: 10.1111/j.1600-6143.2004.00411.x. Am J Transplant. 2004. PMID: 15084173 Free article.

3

Current opinions on therapeutic drug monitoring of immunosuppressive drugs.

Shaw LM, Holt DW, Keown P, Venkataramanan R, Yatscoff RW. Shaw LM, et al. Among authors: holt dw. Clin Ther. 1999 Oct;21(10):1632-52; discussion 1631. doi: 10.1016/S0149-2918(99)80044-7. Clin Ther. 1999. PMID: 10566561 Free article.

4

Therapeutic monitoring of mycophenolic acid. A consensus panel report.

Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P, Morris RG. Shaw LM, et al. Among authors: holt dw. Clin Biochem. 1998 Jul;31(5):317-22. doi: 10.1016/s0009-9120(98)00040-x. Clin Biochem. 1998. PMID: 9721428 Free article. Review. No abstract available.

5

Tacrolimus dose in black renal transplant recipients.

Vadivel N, Garg A, Holt DW, Chang RW, MacPhee IA. Vadivel N, et al. Among authors: holt dw. Transplantation. 2007 Apr 15;83(7):997-9. doi: 10.1097/01.tp.0000259248.60448.8a. Transplantation. 2007. PMID: 17460575 No abstract available.

6

Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.

van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RD. van Gelder T, et al. Among authors: holt dw. Transplantation. 2008 Oct 27;86(8):1043-51. doi: 10.1097/TP.0b013e318186f98a. Transplantation. 2008. PMID: 18946341 Clinical Trial.

7

A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.

MacPhee IA, Holt DW. MacPhee IA, et al. Among authors: holt dw. Transplantation. 2008 Jan 27;85(2):163-5. doi: 10.1097/TP.0b013e3181609054. Transplantation. 2008. PMID: 18212618

8

Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements.

Fredericks S, Moreton M, Reboux S, Carter ND, Goldberg L, Holt DW, MacPhee IA. Fredericks S, et al. Among authors: holt dw. Transplantation. 2006 Sep 15;82(5):705-8. doi: 10.1097/01.tp.0000234942.78716.c0. Transplantation. 2006. PMID: 16969296

9

Long-term evaluation of analytical methods used in sirolimus therapeutic drug monitoring.

Holt DW, Mandelbrot DA, Tortorici MA, Korth-Bradley JM, Sierka D, Levy DI, See Tai S, Horowitz GL. Holt DW, et al. Clin Transplant. 2014 Feb;28(2):243-51. doi: 10.1111/ctr.12305. Epub 2014 Jan 30. Clin Transplant. 2014. PMID: 24476346

10

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW. MacPhee IA, et al. Among authors: holt dw. Am J Transplant. 2004 Jun;4(6):914-9. doi: 10.1111/j.1600-6143.2004.00435.x. Am J Transplant. 2004. PMID: 15147425 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

326 results

Search Page

Filters